1356 DM926, a novel anti-LILRB1/LILRB2 dual antagonist antibody, promotes adaptive and innate immune response to enhance anti-tumor activity in preclinical models
Journal for ImmunoTherapy of Cancer（2023）
Key words
anti-lilrb1/lilrb2,dual antagonist antibody,innate immune response,anti-tumor
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined